Delayed Anti-Nogo-A Antibody Application after Spinal Cord Injury Shows Progressive Loss of Responsiveness
Rattachement africain : ch, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Blocking the function of the myelin protein Nogo-A or its signaling pathway is a promising method to overcome an important neurite growth inhibitory factor of the adult central nervous system (CNS), and to enhance axonal regeneration and plasticity after brain or spinal cord injuries. Several studies have shown increased axonal regeneration and enhanced compensatory sprouting, along with substantially improved functional recovery after treatment with anti-Nogo-A antibodies, Nogo-receptor antagonists, or inhibition of the downstream mediator RhoA/ROCK in adult rodents. Proof-of-concept studies in spinal cord-injured macaque monkeys with anti-Nogo-A antibodies have replicated these findings; recently, clinical trials in spinal cord-injured patients have begun. However, the optimal time window for successful Nogo-A function blocking treatments has not yet been determined. We studied the effect of acute as well as 1- or 2-weeks delayed intrathecal anti-Nogo-A antibody infusions on the regeneration of corticospinal tract (CST) axons and the recovery of motor function after large but anatomically incomplete thoracic spinal cord injuries in adult rats. We found that lesioned CST fibers regenerated over several millimeters after acute or 1-week-delayed treatments, but not when the antibody treatment was started with a delay of 2 weeks. Swimming and narrow beam crossing recovered well in rats treated acutely or with a 1-week delay with anti-Nogo-A antibodies, but not in the 2-week-delayed group. These results show that the time frame for treatment of spinal cord lesions with anti-Nogo-A antibodies is restricted to less than 2 weeks in adult rodents.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Delayed Anti-Nogo-A Antibody Application after Spinal Cord Injury Shows Progressive Loss of Responsiveness
- Date Crossref
- 01/02/2012
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Zurich Brain Research Institute pays non établi dans la noticeUniversité ou école supérieure
-
Stadtspital Waid pays non établi dans la noticeÉtablissement de santé
-
ZHAW Zurich University of Applied Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Novartis (Switzerland) pays non établi dans la noticeEntreprise
-
Novartis (Netherlands) pays non établi dans la noticeEntreprise
-
ETH Zurich pays non établi dans la noticeUniversité ou école supérieure
-
Institute for Biomedical Engineering pays non établi dans la noticeStructure de recherche
-
UniversitätsSpital Zürich pays non établi dans la noticeInstitution
-
Novartis Pharma pays non établi dans la noticeInstitution
-
Novartis International AG Basel Switzerland pays non établi dans la noticeInstitution
Brain Research Institute — University of Zurich, Stadtspital Waid et ZHAW Zurich University of Applied Sciences, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.